Internal Medicine - Issue 12/2018
Guidelines
1124
A summary of the EAS consensus concerning the causal relationship between low-density lipoproteins and atherosclerotic cardiovascular diseases, prepared by the Board of the Czech Society for Atherosclerosis
Vladimír Soška, David Karásek, Vladimír Bláha, Renata Cífková, Tomáš Freiberger, Pavel Kraml, Jan Piťha, Hana Rosolová, Tomáš Štulc, Zuzana Urbanová, Michal Vrablík
News
1131
Consensus statement of professional associations on prescribing of PCSK9-inhibitors
Richard Češka, Miloš Táborský, Michal Vrablík
Actualities
1137
1142
Inflammation and atherosclerosis
Rudolf Poledne, Ivana Králová Lesná
1148
Bilirubin: from an unimportant waste product to important myocardial infarction predictor
Jaroslav A. Hubáček, Libor Vítek
1153
1156
Current views on metabolic syndrome
Štěpán Svačina
1160
1169
1177
Combined lipid-lowering therapy
David Karásek
1186
PCSK9 inhibitors and diabetes mellitus
Branislav Vohnout, Jana Lisičanová, Andrea Havranová
Original Contributions
1190
The changes in cardiovascular prevention practice between 1995–2017 in the Czech Republic: a comparison of EUROASPIRE I, II, III, IV and V study
Otto Mayer Jr, Jan Bruthans, Martina Rychecká Za Investigátory Studií Euroaspire I V V České Republice
Internal Medicine
2018 Číslo 12
Najčítanejšie v tomto čísle
- Lipoprotein(a) – the cardiovascular risk factor: significance and therapeutic possibilities
- Current views on metabolic syndrome
- Why not to interfere with LDL-cholesterol freefall and why not to talk badly about statins
- Combined lipid-lowering therapy